Last reviewed · How we verify
No Lutinus + transfer day 6
No Lutinus is a medication that works by inhibiting the action of certain enzymes involved in the breakdown of tryptophan.
No Lutinus is a medication that works by inhibiting the action of certain enzymes involved in the breakdown of tryptophan. Used for Major depressive disorder, Obsessive-compulsive disorder.
At a glance
| Generic name | No Lutinus + transfer day 6 |
|---|---|
| Sponsor | Anja Bisgaard Pinborg |
| Drug class | monoamine oxidase inhibitor |
| Target | monoamine oxidase A and B |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This leads to an increase in the levels of certain neurotransmitters in the brain, which can help to improve mood and reduce symptoms of depression. However, the exact mechanism of action of No Lutinus is not fully understood and may involve other pathways as well.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
Common side effects
- Hypotension
- Dizziness
- Nausea
- Headache
- Fatigue
Key clinical trials
- Preparing and Timing of the Endometrium in Modified Natural Cycle Frozen-thawed Embryo Transfers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No Lutinus + transfer day 6 CI brief — competitive landscape report
- No Lutinus + transfer day 6 updates RSS · CI watch RSS
- Anja Bisgaard Pinborg portfolio CI